Literature DB >> 30239397

Patient and Physician Preferences for Nonoperative Management for Low Rectal Cancer: Is It a Reasonable Treatment Option?

Erin D Kennedy, Anna M Borowiec1, Selina Schmocker2, Charles Cho, James Brierley3,4, Shirley Li5, J Charles Victor6,7, Nancy N Baxter6,8,7,9.   

Abstract

BACKGROUND: Although the body of evidence supporting nonoperative management for rectal cancer has been accumulating, there has been little systematic investigation to explore how physicians and patients value the tradeoffs between oncologic and functional outcomes after abdominal perineal resection and nonoperative management.
OBJECTIVE: The purpose of this study was to elicit patient and physician preferences for nonoperative management relative to abdominal perineal resection in the setting of low rectal cancer.
DESIGN: We conducted a standardized interviews of patients and a cross-sectional survey of physicians. SETTINGS: Patients from 1 tertiary care center and physicians from across Canada were included. PATIENTS: The study involved 50 patients who were previously treated for rectal cancer and 363 physicians who treat rectal cancer.
INTERVENTIONS: Interventions included standardized interviews using the threshold technique with patients and surveys mailed to physicians. MAIN OUTCOMES MEASURES: We measured absolute increase risk in local regrowth and absolute decrease in overall survival that patients and physicians would accept with nonoperative management relative to abdominal perineal resection.
RESULTS: Patients were willing to accept a 20% absolute increase for local regrowth (ie, from 0% to 20%) and a 20% absolute decrease in overall survival (ie, from 80% to 60%) with nonoperative management relative to abdominal perineal resection, whereas physicians were willing to accept a 5% absolute increase for local regrowth (ie, from 0% to 5%) and a 5% absolute decrease in overall survival (ie, from 80% to 75%) with nonoperative management relative to abdominal perineal resection. LIMITATIONS: Data were subject to response bias and generalizable to only a select group of patients with low rectal cancer.
CONCLUSIONS: Offering nonoperative management as an option to patients, even if oncologic outcomes are not equivalent, may be more consistent with the values of patients in this setting. See Video Abstract at http://links.lww.com/DCR/A688.

Entities:  

Mesh:

Year:  2018        PMID: 30239397     DOI: 10.1097/DCR.0000000000001166

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  6 in total

1.  Long-term oncological outcomes after local excision of T1 rectal cancer.

Authors:  J W A Leijtens; L J H Smits; T W A Koedam; R G Orsini; S M van Aalten; M Verseveld; P G Doornebosch; E J R de Graaf; J B Tuynman
Journal:  Tech Coloproctol       Date:  2022-08-27       Impact factor: 3.699

Review 2.  Nonoperative Management for Rectal Cancer.

Authors:  Felipe F Quezada-Diaz; J Joshua Smith
Journal:  Hematol Oncol Clin North Am       Date:  2022-05-11       Impact factor: 2.861

Review 3.  Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial.

Authors:  Paolo Goffredo; Felipe F Quezada-Diaz; Julio Garcia-Aguilar; J Joshua Smith
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 4.  The impact of bowel dysfunction on health-related quality of life after rectal cancer surgery: a systematic review.

Authors:  F Al Rashid; A S Liberman; P Charlebois; B Stein; L S Feldman; J F Fiore; L Lee
Journal:  Tech Coloproctol       Date:  2022-03-03       Impact factor: 3.699

Review 5.  Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples.

Authors:  Seth I Felder; Sebastian Feuerlein; Arthur Parsee; Iman Imanirad; Julian Sanchez; Sophie Dessureault; Richard Kim; Sarah Hoffe; Jessica Frakes; James Costello
Journal:  Abdom Radiol (NY)       Date:  2020-10-28

6.  Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With "Good Prognosis" Rectal Cancer Eligible for Primary Surgery: The Phase 2 Nonrandomized QuickSilver Clinical Trial.

Authors:  Erin D Kennedy; Marko Simunovic; Kartik Jhaveri; Richard Kirsch; Jim Brierley; Sébastien Drolet; Carl Brown; Patrick M Vos; Wei Xiong; Tony MacLean; Selliah Kanthan; Peter Stotland; Simon Raphael; Gil Chow; Catherine A O'Brien; Charles Cho; Cathy Streutker; Raimond Wong; Selina Schmocker; Sender Liberman; Caroline Reinhold; Neil Kopek; Victoria Marcus; Alexandre Bouchard; Caroline Lavoie; Stanislas Morin; Martine Périgny; Ann Wright; Katerina Neumann; Sharon Clarke; Nikhilesh G Patil; Thomas Arnason; Lara Williams; Robin McLeod; Gina Brown; Alex Mathieson; Amandeep Pooni; Nancy N Baxter
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.